BlackRock Fund Advisors’s Coherus Oncology CHRS Stock Holding History

BlackRock Fund Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$43.9M	Buy	1,559,843 +170,041	+12%	+$4.76M	0.01%	1763
2016 Q3	$37.2M	Buy	1,389,802 +121,067	+10%	+$3.3M	0.01%	1770
2016 Q2	$21.4M	Buy	1,268,735 +148,600	+13%	+$2.79M	﹤0.01%	1985
2016 Q1	$23.8M	Buy	1,120,135 +33,124	+3%	+$543K	0.01%	1886
2015 Q4	$25M	Buy	1,087,011 +468,844	+76%	+$12.1M	0.01%	1907
2015 Q3	$12.4M	Buy	618,167 +61	+0%	+$1.86K	﹤0.01%	2274
2015 Q2	$17.9M	Buy	+618,106	New	+$15.6M	﹤0.01%	2183

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock Fund Advisors's CHRS Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Coherus Oncology (CHRS) stake by 12% in Q4 2016, buying an estimated $4.76M and bringing the position to 1,559,843 shares worth $43.9M. The position accounts for 0.01% of the portfolio, ranked #1763.

BlackRock Fund Advisors first reported a position in CHRS in Q2 2015 and has held it in 7 quarters since. 122 funds tracked by Wall St. Rank hold CHRS as of Q4 2016.

BlackRock Fund Advisors held 1,559,843 shares of Coherus Oncology worth $43.9M as of Q4 2016.
BlackRock Fund Advisors bought 170,041 Coherus Oncology shares in Q4 2016, an estimated $4.76M.
Coherus Oncology made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1763 holding.
BlackRock Fund Advisors first reported a position in Coherus Oncology in Q2 2015 and has held it in 7 quarters since.
122 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.